ICU Medical, Inc. (ICUI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates solid financial performance with increased EBITDA and EPS guidance, strong cash flow, and strategic debt management. Product development is on track, with no sales impact from pending clearances. Operational improvements are expected to enhance margins, and the company is optimistic about its backlog and product refresh cycle. Although tariffs impact costs, structural mitigation efforts are underway. The Q&A reveals a stable market environment and positive analyst sentiment, with no significant risks highlighted. Given the company's market cap, these factors suggest a positive stock price movement of 2% to 8%.
Key Financial Performance
Revenue for Q4 $536 million, total company growth of 2% on an organic basis or minus 14% reported. The decrease in reported revenue is due to the mid-2025 creation of the Otsuka ICU Medical JV and resulting deconsolidation of IV solutions from the income statement.
Full year 2025 revenue growth 5% organic growth for the company. The growth is attributed to operational stability and innovation in product lines.
Gross margins Above 40%. The margin benefits from the deconsolidation of the IV Solutions business and ongoing capture of integration synergies.
EBITDA for Q4 $98 million, a decrease of 7% year-over-year from $106 million. The decline is due to the deconsolidation of the IV Solutions business and tariffs, which had a combined impact of approximately $25 million.
Adjusted diluted EPS for Q4 $1.91, a decline of 9% year-over-year from $2.11. The decline reflects the impact of tariffs and the deconsolidation of the IV Solutions business.
Consumables business Q4 growth 6% reported and 5% organic. The growth is attributed to operational stability and innovation in product lines.
Consumables business full year growth 7% reported and 6% organic. Growth is driven by high single-digit levels in infusion consumables, oncology, and tracheostomy product lines.
IV systems business Q4 growth 3% reported and 1% organic. Growth was impacted by a strong Q4 2024 for pumps and some installations being pulled into Q3 2025.
Vital Care Q4 performance Decreased 6% on an organic basis and 35% reported due to the deconsolidation of IV solutions. The decline is also attributed to the discontinuation of low or negative profit SKUs.
Adjusted gross margin for Q4 40.5%, in line with guidance of 40% to 41%. The margin benefits from the deconsolidation of the IV Solutions business and integration synergies, but was impacted by $11 million in tariffs.
Adjusted SG&A expense for Q4 $113 million. The expense reflects deferred spending and general cost controls.
Adjusted R&D expense for Q4 $21 million. The expense supports various initiatives for long-term revenue growth.
Free cash flow for Q4 $44 million. The cash flow was strong despite the cash impact from higher tariffs.
Net debt at year-end 2025 Just below $1 billion. The company repaid $30 million of principal on its Term Loan B during Q4, bringing total debt principal payments for the full year to $303 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medfusion 5000 syringe pumps and CADD ambulatory pumps: Progress in obtaining new 510(k) approvals and related LifeShield safety software to modernize infusion hardware devices.
Plum Duo and Solo products: Higher ASPs expected to drive revenue growth in the back half of 2026.
Geographic demand: Broad demand and utilization environment attractive across almost every geography, with U.S. experiencing a sharp flu spike.
IV systems business: Growth driven by implementations of Plum Duo and Solo from competitive wins, weighted towards the back half of 2026.
Manufacturing integration: Completion of integration of two large legacy Smiths Medical manufacturing sites, expected to yield benefits as bridge inventory depletes.
ERP system: Full order-to-cash conversion for Europe, with most of the company now on a single modern ERP system, enabling future synergies in logistics and customer service.
Vital Care business: Focus on improving profitability by discontinuing loss-making SKUs and harvesting low-profit SKUs.
Capital allocation: Prioritization of free cash flow towards debt paydown, with a long-term leverage target of 2x.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs: The company faced $11 million in tariff expenses in Q4, with a year-over-year impact of $25 million on adjusted EBITDA. Tariffs are expected to continue impacting gross margins in 2026, representing approximately 2% of revenue.
Deconsolidation of IV Solutions: The mid-2025 creation of the Otsuka ICU Medical JV led to the deconsolidation of IV Solutions, negatively impacting reported revenue and EBITDA. This contributed to a $25 million year-over-year decline in adjusted EBITDA.
Currency Fluctuations: The strengthening of the Mexican peso has increased manufacturing costs, negatively impacting gross margins. Currency is expected to be favorable in Q1 2026 but closer to neutral for the rest of the year.
Manufacturing and Supply Chain Integration: The integration of legacy Smiths Medical manufacturing sites and supply chain projects has been costly and time-consuming. Although nearing completion, these projects have consumed significant cash and delayed cost savings.
Vital Care Business Challenges: The Vital Care segment has been decreasing, with a 6% organic decline in Q4 and a 35% reported decline due to the deconsolidation of IV Solutions. The company is discontinuing low or negative profit SKUs, which will impact near-term revenue.
Regulatory and Quality Compliance: The company received an FDA warning letter in early 2025, which required significant remediation efforts. While progress has been made, these efforts have consumed resources and delayed other initiatives.
Interest Rates: Higher interest rates have increased net interest expenses, which are expected to be approximately $70 million in 2026, impacting overall profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: ICU Medical expects full-year 2026 consolidated organic revenue growth in the low to mid-single-digit range. Consumables and infusion systems are projected to grow mid-single digits, while Vital Care is expected to remain flat or slightly decline.
Gross Margin: The adjusted gross margin for 2026 is projected to be around 41%, with improvements expected throughout the year as manufacturing consolidation and supply chain integration projects are completed.
Adjusted EBITDA: The 2026 adjusted EBITDA is expected to range between $400 million and $430 million, reflecting impacts from tariffs and the deconsolidation of the IV Solutions business.
Adjusted EPS: The adjusted EPS for 2026 is projected to be between $7.75 and $8.45 per share.
Free Cash Flow: Free cash flow is expected to improve in 2026 compared to 2025, driven by higher earnings and reduced spending on restructuring and integration.
Capital Allocation: Free cash flow in 2026 will be prioritized towards debt paydown, with a long-term leverage target of 2x expected to be achieved by early 2027.
Infusion Systems Growth: Growth in the infusion systems segment will be driven by implementations of Plum Duo and Solo products, with higher growth expected in the back half of 2026.
Consumables Growth: Consumables growth will be driven by volume increases from share gains in core infusion lines and higher growth markets for oncology and niche categories.
Currency Impact: Currency is expected to be favorable to reported revenue growth in Q1 2026 and closer to neutral for the remainder of the year.
Tariff Impact: Tariffs are expected to impact gross margins by approximately 2% of revenue in 2026.
Long-Term Revenue Sustainability: ICU Medical expects sustained revenue growth in infusion systems and consumables, supported by innovation and expanded capacities. The company anticipates a long-term refresh of its pump installed base starting in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Share Repurchase Program: The company has prioritized debt paydown with any free cash flow generated during 2026. Once the long-term leverage target of 2x is reached, any free cash flow will then be available for share repurchases. The expectation is to reach the targeted leverage by the beginning of 2027 based solely on organic cash flows, with the possibility to accelerate this timing from proceeds of any potential transactions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the current environment for customers making decisions regarding systems, particularly in light of double-digit LVP growth?
A:The capital environment has been very stable over the last six quarters, with deals getting done. Improvements in the company's share base are meaningful to the P&L, though not necessarily accelerated.
Q:Is the vast majority of pump business on the LVP side currently Duo and Solo?
A:Domestically in the U.S., yes. Internationally, the 60 model continues to be placed.
Q:Are pending clearances impacting infusion system sales, particularly syringe and ambulatory systems?
A:No, pending clearances are not slowing sales. Customers interested in the platform are engaging with the future roadmap.
Q:What is the timing for the pending clearances?
A:The company is pleased with the regulatory response and dialogue. While there is no definitive timeline, they are aiming for midyear (2Q).
Q:What is the appetite for strategic choices following the closure of the warning letter?
A:The company is in a better position to explore opportunities now that certain assets are no longer covered under the warning letter and integration work is behind them.
Q:What are you seeing in terms of underlying volume across hospitals and other end markets for consumables?
A:The guidance for consumables remains mid-single-digit growth, consistent with the last two years. While growth rates in the back half of the year were lower than the previous year, underlying demand remains positive with no significant impact from hospital utilization.
Q:Are there any changes in geographic exposure or mitigation efforts regarding tariffs?
A:There are no significant changes in geographic exposure. Structural efforts to mitigate tariffs have shown some favorability, but more work is needed, with benefits expected later in the year.
Q:Why is the syringe pump a smaller portion of the infusion system business?
A:The syringe pump market is much smaller than the LVP market, representing only 10-20% of its size. However, the company's share in syringe pumps is higher, and it remains an important segment for customers.
Q:Can you provide details on the EBIT or EBITDA margins for the Vital Care business?
A:The infrastructure of Vital Care is deeply co-mingled, making precise assessment difficult. Most of Vital Care is likely below the corporate gross margin, and the company aims for any potential sale to be neutral to earnings.
Q:What is the outlook for the systems business in 2026, considering competitive challenges and new product cycles?
A:The company feels good about its backlog and contracted transactions. While competitive challenges exist, the business has grown despite headwinds from an OEM wind-down over the last two years.
Q:What is the impact of stronger ASPs on Solo and Duo pumps?
A:The new pumps have higher ASPs, contributing to improved gross margins and revenue. The hardware now generates more positive gross margins, which is significant for the business.
Q:How are operational improvements impacting gross margin and SG&A lines?
A:Operational improvements, including IT system integration and manufacturing consolidation, are expected to show benefits in gross margin and free cash flow by the end of 2027.
Q:What is the status of consolidation initiatives and their impact on margins?
A:Consolidation initiatives are nearing completion, with benefits expected to be in the run rate by the end of this year and annualized into next year. These initiatives contribute to the 200 bps margin improvement target.
Q:What is the outlook for free cash flow as restructuring expenses wind down?
A:Restructuring expenses are expected to decrease significantly by midyear, leading to improved free cash flow. The company anticipates free cash flow to exceed $200 million in the future.
Q:What is the company's confidence level in the refresh cycle for its installed base?
A:The company is confident in its ability to refresh its installed base, as customers have remained committed to the core technology despite challenges. The new products offer better features and integration, making them attractive to customers.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the precise timing of pending clearances, stating only that they are pleased with the regulatory response and aiming for midyear. Additionally, they did not provide specific EBIT or EBITDA margins for the Vital Care business, citing co-mingled infrastructure and the complexity of assessment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
IV solution
IV system
Medical acquisition
OEM
Plum Duo
SKUs
Smiths Medical
assumption term
capital allocation
capture
chain
closure
consumables
course
currency
decline
decrease
detail product
digit assumption
flow cash
flow generation
housekeeping update
impact
interest rate
item tariff
legacy Smiths
leverage
oncology
organic
peso
principal
rate share
spending
syringe pump
system integration
target
tariff cash
tariff expense
term calendarization
term outlook
unit
year digit
ICUI Transcript
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.
ICU Medical, Inc. (ICUI) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary indicates solid financial performance with increased EBITDA and EPS guidance, strong cash flow, and strategic debt management. Product development is on track, with no sales impact from pending clearances. Operational improvements are expected to enhance margins, and the company is optimistic about its backlog and product refresh cycle. Although tariffs impact costs, structural mitigation efforts are underway. The Q&A reveals a stable market environment and positive analyst sentiment, with no significant risks highlighted. Given the company's market cap, these factors suggest a positive stock price movement of 2% to 8%.
ICU Medical, Inc. (ICUI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ICU Medical, Inc. (ICUI) Q3 2025 Earnings Call Transcript
Positive11-6
The company's Q3 results show strong financial performance with improved gross margins and EPS growth. The Consumables and IV Systems segments performed well, despite challenges in the Vital Care segment. Management's cautious optimism and strategic focus on growth areas like Consumables and Systems, coupled with efforts to mitigate tariff impacts, support a positive outlook. The market cap suggests moderate volatility, leading to a predicted positive stock price movement of 2% to 8%.
ICUI Slides
ICUI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
